دسته بندی: آنتی بادیهای ایمونوهیستوشیمی

Name: Anti-AMACR/p504s+Anti-p63 human cocktail (PIN cocktail) clone 13H4+4A4

Description and aplications: The main use of the combination of both antibodies in a single reagent is simultaneously immunostain prostate glands in order to detect whether or not neoplastic. In the case of prostate adenocarcinoma, neoplastic glands must present cytoplasmic staining produced by expression of p504s and absence of nuclear staining as these glands lack basal cells and thus are negative for p63. Normal or hyperplastic glands must present nuclear staining in the basal cell layer. The Due to the different pattern of staining of the antibodies included in the cocktail, the detection could be realised with a polyvalent HRP detection systems. Nevertheless, as the antibodies are developed in two different host, a dual detection system can be used.

Composition: anti-human AMACR/p50s rabbit monoclonal antibody + anti-human p63 mouse monoclonal antibody prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Human AMACR polypeptide + aminoacids 1-250 of the N-terminal portion of the human p63 protein

Name: PMS2 Monoclonal Antibody clone EP51

Description and aplications: PMS2, a mismatch repair endonuclease, is a member of a family of genes involved in DNA mismatch repair. Carriers of the mismatch repair gene mutations have a high lifetime risk of developing Hereditary Non-Polyposis Colon Cancer (HNPCC) and several other cancers including endometrial cancer due to microsatellite instability (MSI) caused by accumulation of DNA replication errors in proliferating cells. Along with MLH1, MSH2 and MSH6, PMS2 antibody is helpful in diagnosis of MSI. An IHC study conducted by Mayo clinic on 535 cases with MSI-high, 90% of the tumors showed loss of MLH1, MSH2 and/or MSH6 expression, while 70% of the remaining cases showed isolated loss of PMS2 expression. The loss of PMS2 was associated with young age of diagnosis and right-sided location but not with a striking family history of cancer. Endometrial carcinomas are the most common noncolorectal cancers occur in HNPCC. The most common IHC abnormality in endometrial carcinomas with MSI was concurrent loss of MLH1/PMS2. Adding of PMS2 and MSH6 to MLH1 and MSH2 antibodies increased sensitivity for diagnosis of MSI. Tumors with low-level MSI show unfavourable pathological characteristics compared to tumours with no and tumours with highlevel MSI.

Composition: anti-human PMS2 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: A synthetic peptide corresponding to residues in human PMS2 protein

Name: SOX-11 Antibody clone MD-58 also known as MRQ-58

Description and applications:Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature Bcell neoplasms and is an aggressive disease genetically characterized by overexpression of cyclin D1 (CCND1) due to the specific translocation t(11;14)(q13;q32). It is necessary that MCL be distinguished from potential morphologic mimics, including chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) based on immunohistochemical (IHC) staining for CD5, CD23, and CD10. MCL and CLL both express CD5 but MCL, in contrast to CLL, generally lacks CD23 expression by IHC. FL lacks expression of both CD5 and CD23 but most often expresses CD10, whereas MZL is typically negative for all 3 antigens. Cyclin D1 overexpression is thus the hallmark of MCL even though approximately 5%-10% of MCLs lack Cyclin D1 expression and may be misdiagnosed by overreliance on CyclinD1 IHC. The recognition of cyclin D1-negative MCL is difficult because it may resemble other small B-cell lymphomas morphologically and phenotypically. Although the clinical information on cyclin D1negative MCL is limited, published data indicate that the behaviour of the variant is as aggressive as that of conventional MCL. On the other hand, patients with small B-cell lymphomas mimicking MCL have a significantly better outcome than those with true MCL. It is, therefore, important to find reliable biomarkers that may allow the identification of cyclin D1-negative MCL in clinical practice. SOX-11, the SRY (sex-determining region Y)-box11 gene, a transcription factor, normally is expressed in the developing human central nervous system, medulloblastoma, and glioma. In a series study, SOX- 11 expression was investigated in 54 cyclin D1positive MCL and 209 other lymphoid neoplasms. Interestingly, nearly all MCL were strongly positive for anti-SOX-11 (50/54, 93%), with a nuclear pattern. The staining was intense and relatively homogeneous in most of the cells. Compared to anti-cyclin D1 staining, anti-SOX-11 reactivity was stronger and more homogeneous. Five T-cell and B-cell lymphoblastic leukemia/lymphomas showed strong SOX-11 nuclear expression. One case of classic Hodgkin lymphoma, two of eight BL and two of three T-cell prolymphocytic leukemias were also positive. SOX-11 protein expression was examined by immunohistochemistry in the 12 cyclin D1-negative MCL, and all of them showed strong nuclear positive staining similar to that occurring in conventional cyclin D1-positive MCL. The expression of SOX-11 in reactive tonsil, lymph node and spleen specimens was studied. No nuclear expression was observed in any lymphocyte compartment. Only cytoplasmic staining was seen in cells from reactive germinal centers. Therefore, the authors confirmed prior reports that SOX-11 nuclear expression was a specific marker for MCL, including cyclin D1-negative MCL with typical morphology. Their study indicates that SOX-11 IHC is of value in further defining pathologic features of CD5+ DLBCL. Routine use of anti-SOX-11 in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-negative blastoid MCL. In summary, nuclear protein expression of SOX-11 is highly associated with both cyclin D1-positve and negative MCL. The detection of this transcription factor is a useful biomarker for identifying true cyclin D1- negative MCL. SOX-11 IHC is of value in further defining pathologic features of CD5+ DLBCL. Routine use of anti-SOX-11 in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-  negative blastoid MCL. SOX-11 can also be detected in some BL, LBL and T-PLL, although the different morphological and phenotypic features of these malignancies allow easy recognition of the cases of cyclin D1-negative MCL

Composition:Anti-human SOX-11 mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: L1CAM Antibody clone BSR3

Description and applications:L1CAM (L1 cell adhesion molecule protein) is a cell adhesion molecule with an important role in the development of the nervous system. The L1, neural cell adhesion molecule (L1CAM) plays an important role in axon growth, fasciculation, neural migration and in mediating neuronal differentiation. L1 protein is expressed to tissues arising from neuroectoderm. L1CAM plays also an important role in the malignancy of human tumors and according to several studies, L1CAM positive carcinomas have a bad prognosis. L1CAM is overexpressed in many human carcinomas but it is useful especially in endometrium carcinoma diagnostic.

Composition : Anti-human L1CAM rabbit monoclonal antibody purified from culture supernatant, filtered, sterilized and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: p21/Waf-1 (DCS-60.2)

Description and aplications: p21WAF1/Cip1/Sdi1/Pic1 is a tumor suppressor protein. Expression of p21WAF1 is induced by wild type, but not mutant, p53 suppressor protein. The p21WAF1 protein binds to cyclin/CDK complexes and inhibits their kinase activity thereby stopping cell cycle progression. It also binds to PCNA (proliferating cell nuclear antigen) and blocks DNA replication but not the DNA repair process.

Composition: anti-human p21 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Visualization: Nuclear

Name: Cytokeratin 7 Antibody clone OV-TL 12/30

Description and aplications: Keratins (also known as cytokeratins) are intermediate filament/forming proteins that represents the main cytoskeleton of epithelial cells. They classically are classified based on Moll cataloging which grouped the basic-to-neutral type II keratins as K1–K8 and the acidic type I keratins as K9– K19. An updated classification including 24 types of keratins was then proposed in order to enable other mammalian species keratins to be added. This monoclonal antibody reacts specifically with the cytokeratin 7, immunostaining of the producing a protein band of 54 kD in the cytoskeleton of cell lines and uni-dimensional immunoblots. This antibody is useful to distinguish between different types of normal glandular epithelia as it marks the epithelia of lung and breast, being negative for colon and prostate. We have not observed any cross reaction with other cytokeratins and overall this antibody does not react with stratified squamous epithelium. In liver, hepatocytes are negative and the epithelial cells of the bile ducts are positive. This antibody reacts with numerous both benign and malignant epithelial lesions. Cytokeratin 7 is expressed in specific subtypes of ovarian adenocarcinomas, breast and lung carcinomas while the gastrointestinal tract, except stomach, are negative. Carcinomas arising from transitional epithelium also express cytokeratin, whereas prostate cancer is generally negative.

Composition: anti human keratin 7 mouse monoclonal antibody obtained from supernatant culture and prediluted in a Tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: OTN II ovarian carcinoma cell line

Name: Cytokeratin 8 antibody clone EP17

Description and aplications: Cytokeratin 8 (CK8) is an intermediate filament protein produced early in embryogenesis. It is the only type-II CK occurring in many simple epithelial in respiratory, gastrointestinal, male and female reproductive tract and thyroid. CK8 is often co-expressed with Cytokeratin 18. CK8/18 is the major keratin pair in simple-type epithelia, as found in the liver, pancreas, and intestine. CK8 antibody is used to detect adenocarcinomas with simple epithelium origin. The difference in staining pattern is useful to distinguish duct (peripheral staining) from lobular (perinuclear staining) breast carcinoma

Composition: anti-human cytokeratin 8 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: A synthetic peptide corresponding on the C-terminus

Name : Cytokeratin 8/18  antibody clone B22.1/B23.1

Description and applications:Cytokeratins 8&18 can be found in most simple epithelium,e.g. thyroid,female breast, gastrointestinal tract, and respiratory tract. Adenocarcinomas and most non-keratinizing squamous carcinomas will stain, but keratinizing squamous carcinomas will not. This antibody is used when attempting to demonstrate the presence of Paget cells; there is very little keratin 18 in the normal epidermis so this will only stain Paget cells. This approach facilitates the interpretation using immunostains and is more sensitive than mucin histochemistry.

Composition:Anti-human Cytokeratin 8/18 cocktail of two mouse monoclonal antibodies purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: Placental Alkaline Phosphatase antibody

Descrioption and aplication: This antibody reacts with a membrane-bound isoenzyme of placental alkaline phosphatase (PLAP) occurring in the placenta during the 3rd trimester of gestation. It is expressed in testicular germ cell tumors. Unlike germ cell tumors, PLAP-positive somatic cell tumors uniformly express epithelial membrane antigen (EMA).

Composition: Anti-human Placental Alkaline Phosphatase rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogeon: Recombinant protein encoding human placental alkaline phosphatase.

Name: DNA-Binding Protein SATB2 Monoclonal Antibody clone EP281

Description and applications: DNA-binding protein SATB2, also known as Special ATrich sequence-binding protein 2, is a nuclear matrixassociated transcription factor. SATB2 acts as a docking site for chromatin remodelling enzymes and recruits co-activators and co-repressors to control nuclear gene expression. SATB2 also regulates skeletal development, osteoblast differentiation, and modulates immunoglobulin expression. In normal tissues, strong nuclear SATB2 expression is observed in essentially all glandular cells lining the lower gastrointestinal tract, including the appendix, colon, and rectum. SATB2 is also expressed in a subset of neuronal cells from the cerebral cortex and hippocampus. In tumor tissues, SATB2 is detected in cancer cells of colorectal origin and may function as a clinically useful diagnostic marker for colorectal cancer (CRC). In a multi-cohort study with 1882 primary and metastatic CRCs, SATB2 shows high sensitivity (85%) for CRC, and further enhanced to 93% when stained in conjunction with Cytokeratin 20. A recent study showed SATB2 expression in 89% of medullary carcinomas of the large intestine. SATB2 has been suggested as a valuable prognostic marker: high SATB2 expression was determined as an independent marker of good prognosis and sensitivity to chemotherapy and radiation in CRC while loss of SATB2 expression was correlated with poor prognosis in laryngeal carcinoma patients.

Composition: Anti-human SATB2 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: CEAm Antibody clone COL-1

Description and applications: This antibody has a high affinity for CEA and shows no detectable reactivity to nonspecific cross-reacting antigen (NCA), biliary glycoprotein (BGP) and human polymorphonuclear leucocytes. Ab-3 shows no reaction with a variety of normal tissues .CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).

Composition: anti-human CEA mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting